BIRCH POLLEN ALLERGEN P14 FOR DIAGNOSIS AND THERAPY OF ALLERGIC DISEASES

Abstract: The invention provides recombinant DNA molecules which code for polypeptides that exhibit the antigenicity of a P14 allergen of birch Betula verrucosa and other plants of the order Fagales, and for polypeptides comprising at least one epitope thereof, as well as nucleic acids which under stringent conditions hybridize with such DNA sequences or are derivable from such sequences by degeneracy of the genetic code. A method is provided that permits purification of P14 allergens or cross-reactive allergens by means of binding to poly(L-proline). In addition, methods are described for making the proteins and polypeptides coded by these DNA molecules and their use in the diagnosis or therapy of allergic diseases.

Description: BIRCH POLLEN ALLERGEN P14 FOR DIAGNOSIS AND THERAPY OF ALLERGIC DISEASES 1. FIELD OF THE INVENTION The invention provides recombinant DNA molecules which code for polypeptides, and the polypeptides per se, that have at least one epitope of a P14 pollen allergen of a tree of the order Fagales, particularly birch (Betula verrucosa) , or the entire P14 allergen protein, and exhibit the same or similar antigenicity as a P14 allergen. The invention also provides replicable microbial expression vehicles and microorganisms for use in processes for producing such allergenic polypeptides. Methods are provided for purification of P14 allergen as well as for the diagnosis and therapy of allergic diseases using the synthetic polypeptides of the invention. 2. BACKGROUND OF THE INVENTION In the springtime large parts of the populations of Central, Eastern and Northern Europe, America and Australia suffer from allergic symptoms (rhinitis, conjunctivitis, dermatitis and pollen asthma) . Proteins which can be isolated from pollen of trees of the order Fagales, in particular from pollen of birch, alder, hazel, hornbeam and oak, are responsible for most of these allergic symptoms (1) . At least 10% of the population suffers from pollen allergies at various times and to varying extent. These allergies are mediated by IgE antibodies whic react with pollen proteins. The possibility exists for a therapy for pollen allergies by hyposensitization, i.e., by the regular and slowly increasing administration of the proteins producing the allergy. Diagnostic methods for allergic diseases, such as RIA (radioi munoassay) , IRMA (immuno-radiometric assay) , RAST (radio-allergosorbent test) , ELISA (enzyme- linked immunosorbent assay) , magnetic allergoabsorbent test, immunoblots, LIA (luminescence immunosay) , Histamine release assays and others depend greatly upon the availability of pure allergens. Protein extracts from pollen isolated from natural sources are difficult to standardize because preparations vary from batch to batch. For example, they may contain unwanted constituents, and/or certain proteins may be lost in the extraction procedure and be missing from the final separation (2) . Clearly, diagnostic tests which employ well defined allergens that can be reproducibly prepared would be superior to tests which employ raw pollen extracts with an insufficiently defined mixture of allergens and other components. Recombinant DNA production of allergenic polypeptides, or allergenic fragments thereof, would allow more reproducible preparations of allergens of defined content for standardized diagnostic and therapeutic methods. Allergens may be purified to homogenity from pollen by known protein/chemical methods, for example, by means of affinity chromatography (3). These methods are relatively costly and require pollen as an ill-defined source which cannot be standardized. It would, therefore, be cheaper and more efficient to use recombinant DNA •methods to produce an allergenic protein, or fragments of that protein. Hyposensitization has proved to be an effective therapy in allergic diseases. This therapy consists of parenteral or oral administration of allergens in increasing doses over a fairly long period of time. Like diagnostic methods, it requires pure and well defined allergens. The use of purified recombinant allergens or synthetic peptides wouid greatly reduce the risk of sensitizing patients to unwanted components. 513 -3- 3. SUMMARY OF THE INVENTION This invention concerns pollen allergens, for example, of white birch (Betula verrucosa), called P14. These pollen allergens are immunologically closely related to allergens which occur in pollen of far distantly related plant species, particularly in trees of the Fagales order (birch, alder, hazel, hornbeam and oak) , in grasses and weeds. The cross-reactivity of IgE antibodies of patients to these pollen allergens is illustrated in FIGS. 1A and IB. The present invention provides recombinant DNA molecules which contain a nucleotide sequence that codes for a polypeptide which e ibits the same or similar antigenic properties as a natural allergen, P14, which occurs in trees of the order Fagales and other pollen producing plants, or a polypeptide which comprises at least one epitope of uch allergens. The invention provides the complete cDNA sequence of a P14 allergen and hence the complete deduced amino acid sequence. Additionally, the invention includes (a) nucleotide sequences which hybridize with such a cDNA sequence under high stringency and encode a polypeptide having at least one epitope of a P14 allergen and (b) nucleotide sequences which can be derived from such allergenic polypeptides by degeneracy of the genetic code. This nucleotide sequence can be expressed as a P14 allergen, or as a polypeptide which comprises at least one epitope thereof. In a preferred embodiment, this cDNA sequence contains the whole sequence or parts of the sequence set forth in the Sequence Listing as SEQ ID NO:2. As concerns their IgE binding, pollens of birch, alder, hazel, hornbeam, oak, grasses and weeds possess similar allergens as the P14 allergen. The present invention therefore relates not only to a P14 allergen of birch, but as well to P14 pollen allergens of other species which are coded by DNA sequences that are able to hybridize with the nucleotide sequence of a birch P14 allergen under stringent conditions or can be derived from such polypeptide by degeneracy of the genetic code. Hybri¬ dization of a polynucleotide with another polynucleotide under stringent conditions requires at least a 60 % iden- tity between such polynucleotides at the nucleic acid le¬ vel. Such stringent conditions entail washing of hybridized nitrocellulose filters as follows: a) For DNA/DNA and DNA/RNA hybridizations: A tempera- ture of 55°C, a salt concentration of 150 mM NaCl and 15 mM Na 3 citrate x 2 H 2 0, at pH 7,0, and SDS (Sodium Docedyl Sulfate) detergent at a concentration of 0,1 % (w/v) . (b) For oligodeoxynucleotides/DNA hybridizations: A temperature of 55°C, a salt concentration of IM NaCl and 10 mM Na 3 citrate x 2 H 2 0, at pH 7,0, and SDS (Sodium Dode- cyl Sulfate) detergent at a concentration of 0,5 % (w/v). In this context "oligodeoxynucleotide" refers to an oligo¬ mer of a single stranded DNA of up to 100 nucleotides in length. In addition, this invention provides expression plas- mids that contain a nucleotide sequence as described above and hose cells which harbor these expression plasmids. This invention also provides compositions containing synthetic polypeptides which exhibit the antigenicity of parts or of the whole of a birch P14 allergen or of aller¬ gens of other plants which, because of a high degree (at least 50 %) of amino acid homology, exhibit antigenic cross-reactivity to parts or to all of a birch P14 aller¬ gen, i.e., antibodies or cellular antigen binding sites which are actually directed to birch P14 allergen are li¬ kewise able to bind to these molecules. These synthetic polypeptides include fusion and nonfusion polypeptides which contain a polypeptide portion that possesses the antigenicity of a part or of all of a P14 allergen. The method for preparing such synthetic polypeptides comprises the steps of culturing of prokaryotic or eukaryotic host cells which contain an expression plasmid described above and purification of the synthetic polypeptide(s) from the culture. The term "synthetic" here alternatively includes polypeptides which are prepared by cloning and expression of the nucleotide sequences described here or by chemical synthesis of polypeptides encoded by these nucleotide sequences. The synthetic polypeptides which are produced according to this invention exhibit antigenicity the same as or similar to the native allergen. As shown below, a cDNA clone coding for a birch P14 can be used to produce a nonfusion polypeptide which reacts with IgE in the sera of allergic persons. It is therefore possible to use this polypeptide as an antigen in diagnostic tests (such as RAST, ELISA, Immunoblots and others known in the art and referred to above) and as a component of therapeutic agents in hyposensitization therapy. In particular, the synthetic allergens can be used as diagnostic reagents in vitro and in vivo, since their antigenicity corresponds to that of the native P14 pollen allergens and they are therefore able to bind IgE in sera of persons suffering from P14 pollen allergy. It is therefore one of the objects of the present invention to provide a method for the preparation of polien allergens, in particular for birch P14 allergens, so as to have this family of allergens available for diagnostic tests for detection of the corresponding allergy and, alternatively, for hyposensitization therapy. In addition, as shown below, birch P14 cDNA was expressed in two prokaryotic expression systems in Escherichia coli P and the IgE-binding capacity of the expressed polypeptides, a fusion protein and a nonfusion protein, was demonstrated. This expression can also be -6- achieved in any other microorganism (e.g., eukaryotic cells) . The IgE-binding capacity was also demonstrated for a partial sequence which was expressed, using lambda gtll, as a 6-galactosidase fusion protein. In this way it was demonstrated that this partial sequence represents at least one IgE-binding epitope. In addition, it may be concluded from the results of IgE immunoblots, cross- inhibition tests, clinical tests and Northern (RNA) blots (4-9) (FIGS. 1A, IB and 3) that homologous IgE-binding polypeptides exist in the pollen of closely related trees of the order Fagales and for distantly related pollen producing plants. For this reason this invention provides polypeptides which exhibit the same or similar antigenicity as the related P14 pollen allergens of birch, alder, hazel, hornbeam, oak, grasses and weeds. A computer search in the available sequence data banks (EMBL, MIPSX, Swissprot) for proteins whose sequences share homology with birch P14 revealed a significant homology between P14 and a cytoskeletal protein (profilin) which is present in a variety of eukaryotes (10-14) (FIG. 5) . This homology raises the possibility of the cross-reactivity of IgE antibodies of patients with human profilin. This autoreactivity has been demonstrated (FIG. 12) . In this way, a molecular .system is provided which permits testing the hypothesis: whether autoimmune mechanisms play a role in allergic and atopic diseases. Initial data show that patients whose IgE antibodies react with P14 represent a group that suffers from allergic symptoms during a large part of the year and who do not respond satisfactorily to immunotherapy or conventional therapy. It follows from this that P14, or recombinant or chemically synthesized IgE-binding polypeptides with sequences that match the sequence deduced from P14 cDNA, can be used to characterize a certain group of multivalent allergies as well as a prognostic markers for hyposensitization therapy. In addition, this invention presents an efficient method for the production and purification of pollen protein as well as of recombinant or synthetic P14 polypeptide or allergenic fragments thereof. The purification method is based on the affinity of profilin polypeptides for poly(L-proline) (15, 16) , and the present inventors' showing of homology between profilins and P14 allergens. Since the binding of pollen protein and of recombinant P14 to poly(L-proline) has been shown herein (FIGS. 8, 9 and 10), a method is ther ~τ provided for immobilizing (and affinity separation ) this allergen. Thus, certain diagnostic tests can be c-et up (for example, poly(L-proline) may be used instead of an antibody for binding profilin in ELISAs) . Likewise, forms of therapy are possible which by means of poly(L-proline) bind P14 and analogous polypeptide allergens. Since there are indications that patients who suffer from autoimmune diseases form antibodies against P14, this polypeptide or homologous polypeptides could be used for diagnosis or therapy of these diseases. 4. BRIEF DESCRIPTION OF THE FIGURES The following figures and description aid in understanding the field anc. scope of the invention. FIG. 1A: IgE immunoblot: Pollen proteins from birch (B) , hornbeam (CA) , alder (A) and hazel (C) were separated by means of a 12.5% polyacrylamide electrophoresis and blotted on nitrocellulose. The nitre llulose was cut into strips (1-5) which were incubated with dilutions of a serum (1:5, 1:10, 1:20, 1:40, 1:80, respectively) of a selected patient whose IgE antibodies recognized most important birch pollen allergens. Arrows and stars indicate molecular weights. Bound serum IgΞ was detected by means of an autoradiograph of 125 I-labeled antihuman IgE antibodies of rabbit bound thereto. The IgE-binding proteins of birch, alder, hazel and hornbeam matched one another, which demonstrates the similarity of the antigens. FIG. IB: IgE immunoblot inhibition: mugwort profilin that had been purified by poly(L-proline) affinity chromatography had been blotted on nitrocellulose after polyacrylamide gel electrophoresis. The 1:10 dilution of the serum from a patient allergic to birch profilin was pre-incubated in lane 1 with control proteins from E. coli. in lane 2 with recombinant birch profilin, in lane 3 with purified profilin from Phleum pratense (grass) and in lane 4 with buffer (negative control) and used for detection of mugwort profilin. Binding of patients' IgE to mugwort profilin can be blocked with recombinant birch profilin and purified grass profilin demonstrating common IgE binding properties of these related proteins. In the control lanes 1 and 4 binding of patients' IgE to mugwort profilin occurs. FIG. 2: IgE immunoblot: Proteins were separated by means of a 7.5% polyacrylamide gel electrophoresis and blotted on nitrocellulose. Lane B: birch pollen proteins; lane 1: proteins from E. coli Y1089 (lysogenic host); lane 2: proteins of 12. coli Y1089 inoculated with the lambda gtll phage without insert; lane 3: proteins from E. coli Y1089 inoculated with a recombinant phage containing a birch pollen derived cDNA encoding an IgE binding polypeptide (positive control) ; lane 4: proteins from E. coli Y1089 inoculated with recombinant phages which contain the 3*-portion of P14 cDNA which codes for an IgE-binding epitope (as underlined in FIG. 4); lane 5: proteins from yeast (Saccharomvces cerevisiae) . Recombinant 6-galactosidase fusion proteins with IgE-binding capacity whose molecular weights were between 115 and 130 kD (lanes 3 and 4) were detected with 125 I-labeled antihuman IgE antiserum from rabbit. No comparable IgE binding takes place in lanes 1, 2 and 5, while lane B shows the patient's IgE-binding profile with birch pollen proteins. FIG. 3: Northern (RNA) blot: Ten μg pollen RNA of alder (lane A) , birch (lane B) and hazel (lane C) and as a marker RNA of E. coli (lane M) were blotted on nitrocellulose. The part of the P14 cDNA underlined in FIG. 4 hybridizes with pollen mRNA of alder, birch and hazel and under stringent conditions (0.75 x SSC, 0.1% SDS, 50°C) produces a signal at 800 bases (indicated by an arrow) . The position of ribosomal bands is indicated by "28S" and "18S". FIG. 4: cDNA sequence of birch P14. The coding region begins with ATG (nucleotides 80-82) and ends with the stop codon TAG (nucleotides 479-481) . The deduced amino acid sequence is illustrated under the DNA sequence. The P14 sequence, which within a fusion protein is able to bind IgE of patients and therefore represents at least one epitope, is shown underscored (see Section 5.4). FIG. 5: Comparison of the derived amino acid sequence of birch P14 with the amino acid sequences of profilins of human (13) , calf (14) , mouse (12) , yeast (11) and Acanthamoeba (10) . Identical amino acid residues are marked. The percentage of identical amino acid residues between P14 protein of birch and homologs amounts to 30% for human protein, 28% for homologous proteins of calf and mouse, 26% for yeast protein and 25% for Acanthamoeba protein. FIG. 6: Western (protein) blot of a polyacrylamide gel probed with IgE antibodies of patients with tree pollen allergy. Lane l: proteins of- E. coli JM105 without any plasmid; lane 2: proteins of E. coli JM105 with the plasmid pKK223-3 without an insert; lanes 3 and 4: proteins of IS. coli JM105 with that plasmid derived from pKK223-3 which expresses the P14 protein of the inserted cDNA as nonfusion protein; lane 5: E. coli AR58 proteins; lane 6: ]3. coli AR58 with the plasmid pEXB without an insert; lanes 7 and 8: extracts from £. coli AR58 transformed with the plasmid derived from pEXB which expresses P14 cDNA as fusion protein; lane 9: birch pollen protein extract (positive control) . FIG. 7: Sera from various allergic patients were tested for their IgE reactivity with respect to recombinant P14 which was expressed in pKK223-3. Patients (lanes) D, E, F, I, J, and P show IgE binding to the recombinant P14. Lane R is a serum pool f om non-allergic individuals. The recombinant P14 was not purified and, therefore, reactivity of patients' IgE with proteins from E. coli was seen. FIG. 8: Coomassie stained polyacrylamide gel. Lane M: molecular weight marker; lane 1: total pollen proteins of birch; lane 2: birch pollen proteins from which P14 was removed by the affinity method (flow through) ; lanes 3, 4 and 5: eluted P14. Proteins were applied to the gel and stained to indicate migration. As can be seen f om lanes 3, 4 and 5, P14 can be purified by affinity chromatography to poly(L-proline) sepharose. FIG. 9: IgE immunoblot: A probe of proteins obtained in the same way as in FIG. 8 was transferred to nitrocellulose and incubated with serum IgE of a patient who recognizes most birch pollen allergens. Lanes 1 - 5 contain the same material as in FIG. 8; lane 6 contains the molecular weight marker. This immunoblot shows that birch profilin can be purified to apparent homogeneity from other allergens. FIG. 10: Coomassie-stained polyacrylamide gel. Lane M: molecular weight marker; lane 1: total proteins of E. coli JM105 with the plasmid derived from pKK223-3 that expressed the P14 cDNA; lane 2: protein fraction after removal of the recombinant P14 by affinity chromatography to poly(L-proline) sepharose; lanes 3 and 4: purified recombinant P14-eluted fractions. FIG. 11: Coomassie-stained polyacrylamide gel. Lane M: molecular weight marker; lane l: total protein from E. coli JM105 with the plasmid pKK223-3 without insert; lane 2: protein fraction after poly(L-proline) purification; lanes 3, 4 and 5: eluted fractions. These results show that no protein with similar properties to P14 can be isolated from the expression system without insert. FIG. 12: IgE immunoblot: Purified human profilin was loaded on a 12% polyacrylamide gel and blotted on nitrocellulose. Strips of the nitrocellulose were cut and incubated as follows: Strip l was incubated with serum IgE of a patient who recognized besides P14 and the major birch pollen allergen, Bet v I , allergens in the molecular range between 30 and 90 kD. Strip 2 was incubated with serum IgE from a patient who recognized only P14 in birch pollen extracts; strip 3 was incubated with serum from a patient whose serum IgE was directed only aσainst Bet v I ; strip 4 was incubated with the serum from patient allergic to mites; strip 5 with serum from a group of nonallergic donors and strip 6 shows the buffer control. IgE binding was detected with a I25 I-labeled antihu an IgE antiserum of rabbit. Cross-reactivity was shown for strips 1 and 2. This data demonstrates that serum IgE that reacts with birch pollen also cross-reacts with human profilin. FIG. 13: IgE-inhibition: Purified celery profilin was subjected to SDS-Page, blotted to nitrocellulose (lμg/cm). Nitrocellulose strips where incubated with 1:10 dilutions of sera from birch pollen profilin allergic patients (lanes 1-3), from patients allergic to the major birch pollen allergen Bet v I but not to profilin, a serum pool of nonallergic individuals (lane 4) and with buffer without addition of serum (lane 5). The serum dilutions where preincubated with 5μg of purified recombinant birch profilin each (rP), 5 μg of BSA (BSA), and with serum dilution buffer(P). Binding of IgE of the patients 1-3 to celery profilin can be blocked with purified recombinant birch profilin indicating common IgE epitopes of birch and celery profilin. FIG. 14: Immunoblots: Purified celery profilin (C ) and recombinant birch profilin (rP) is recognized by the rabbit anti celery profilin antibody (R: lane 1). Recombinant birch profilin also binds patients IgE (IgE: lane 1). No binding is seen in lane 2 (buffer control without addition of antibody or serum). FIG. 15: Immunoblots: Purified profilin from rye (Secale cereale S) and from mugwort {Artemisia vulga s M) binds the rabbit anti celery profilin antibody (lanes 1) whereas in the buffer control (lane 2) no bindin was found. Bound rabbit antibody in Figures 14 and 15 was detected with 12 5 J donkey anti rabbit antibody from Amerham, UK. Bound serum Ig in Figures 13 and 14 was detected with I 25 J rabbit anti human Ig from Pharmacia, Sweden. FIG. 16: cDNA and deduced amino acid sequence of profilin from pollen of timothy grass (Phleum pratense) FIG. 17: IgE-binding of patients IgE to plaquelifts of lambda gt 11 phages containing the cDNA insert encoding timothy grass profilin 30 grass pollen allergic patients were tested for IgE binding to lambda gt 11 phages that express profilin from timothy grass whic was bound to nitrocellulose sectors. Sector 31 shows a serumpool from non allergic individuals and sector 32 the buffer control without addition of serum. Serum IgE of patients 2, 6, 7, 8, 9,10,11,12,15,17,18,21,23,26,27,28,29 and 30 bound to the recombinant timothygrass profilin expressed in lambda gt 11. All these patients also displayed IgE reactivity to birch profilin. Patients 1, 3, 4,5,13,14,16,19,20,22,24, and 25 who were allergic to other grass pollen allergens did not show any IgE reactivity to timothy grass profilin. Bound serum IgE was detected as described in Fig. 13. 5. EXAMPLES The invention can be understood by reference to the following examples: 5.1. Construction of the cDNA σene bank Pollen (Allergon AB Engelholm, Sweden) which was examined for purity by means of light and electron microscopy, was used for the isolation of polyadenylated RNA (17, 18). cDNA synthesis was carried out with oligo- dT and random primers (19, 20), the ends of the cDNA were cleanly digested with T4-polymerase and provided with EcoRI-linkers. The cDNA with linkers was ligated and packed in dephosphorylated lambda gtll arms (21) . A cDNA gene bank of 800,000 independent clones was produced. 5.2. Screening of the cDNA σene bank IgE screening of the birch pollen cDNA gene bank was performed as described ( 12 ) . IgE-binding clones were enriched and phage DNA was prepared therefrom (23) . The inserts were cut out with EcoRI and the fragments were subcloned in the plasmid pUC18 (24) . The DNA sequence of a clone was obtained (25) . Although it was complete at the 3'-terminus (poly-A tail), it lacked a part of the 5'- terminus including the start codon as well. This partial sequence i. underscored in FIG. 4. Therefore the original gene bank was again screened with oligodeoxynucleotides which were complementary to the coding region (26) and two independent clones were obtained. 5.3. RNA (Northern) blots Ten μg of total RNA from pollen of alder, birch nd hazel were separated by means of a denaturing gel electrophoresis and blotted on nitrocellulose (27, 28) . A P14 cDNA probe, as underlined in FIG. 4, was 3 P-labeled by means of random priming (29) . Prehybridization and hybridization were carried out by stant. rd methods (1.3) . The blots were washed with 0.75xSSC (20xSSC = 3M NaCl, 0.3M Na citrate, pH 7.0), 0.1 % SDS (sodium dodecyl sulfate) at 50°C and autoradiographed (Hyperfil MP, Amersham, London, UK) . 5.4. Expression of Birch P14 cDNA 5.4.1 Expression of the 3*-terminus of the cDNA in lambda gtll phages (FIG. 2) An incomplete cDNA clone which codes for a part of P14 was obtained by means of IgE screening (22) as described in Section 5.2. The lysogenic E. coli strain Y1089 was inoculated with recombinant lambda gtll phages, containing an insert as underlined in FIG. 4, and the 6-galactosidase fusion protein was recovered from the mixture (19) . The construction would predict that a fusion protein having a molecular weight of 116 kD would be produced. The mixture was subjected to electrophoresis on a 7.5% polyacrylamide gel and was blotted on nitrocellulose. The fusion protein was detected by means of IgE antibodies in patient serum and an iodine-labeled rabbit antihuman IgE antibody (Pharmacia, Uppsala, Sweden) -* (FIG. 2) . As shown in FIG. 2, a fusion protein having a molecular weight of between 115 kD and capable of binding to IgE antibodies was observed. 5.4.2. Expression of complete P14 cDNA 0 as fusion and nonfusion protein The complete cDNA that codes for P14 contains a prokaryotic ribosome binding site (Shine-Dalgarno sequence (30)) and was inserted into the EcoRI sites of plasmids PKK223-3 (31) or pEXB (32) to obtain P14 as a nonfusion 5 protein or a fusion protein of P14 with the lambda ell protein. IgE-binding clones were obtained by means of serum IgE and a colony screening method (33) and were examined by means of DNA restriction analysis. Recombinant proteins were tested for their binding 0 capacity with respect to patient IgE antibodies as described (22) (FIG. 6) . 5.5. Purification of birch pollen P14 and recombinant P14 5 P14 from birch pollen and recombinant P14 were purified by means of an affinity method by a batch process i (cf. 15, 16) which is suitable for the profilins of Acanthamoeba (10), yeast (11) and man (13). Birch pollen and E. coli cells, which contain the plasmid that codes 0 for P14, were lysed in PHEM-TX buffer (2x PHEM-TX: 120 mM PIPES (piperazine-l,4-bis(2-ethanesulfonic acid)), 50 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), 20 mM EGTA (ethylene glycol-bis(6-aminoethyl ether)-N,N,N',N , -tetraacetic acid), 4 M MgCl 2 , 10 mM 35 glucose, 20 μg/ml leupeptin, 156 μg/ml benzamidin, 80 μg/ l aprotinin, 1 mM PMSF (phenylmethyl sulfonyl fluoride) , 1.5% Triton-XlOO, pH 7.2) and the lysate was centrifuged for one hour at 65000 x g at 4°C. The supernatant was incubated overnight at 4°C with poly(L- proline) coupled to BrCN-activated Sepharose 4B (Pharmacia, Uppsala, Sweden) . Then the affinity matrix was washed three times with a double volume each time of TBS-ATP (20 mM TRIS, 150 mM NaCl, 0.5 mM ATP (adenosine triphosphate), pH 7.6) and then eluted for five minutes at room temperature with a double volume of elution buffer I (TBS-ATP with 2M urea) . The supernatant was collected. The procedure was repeated twice with elution buffer II (TBS-ATP with 6M urea) and the supernatants were dialyzed against distilled water at 4°C. The dialysates, which contained the proteins, were lyophilized and analyzed by means of polyacrylamide gel electrophoresis and IgE immunoblot (FIGS. 8, 9, 10 and 11). 5.6. IgE-binding capacity of a protein expressed from a fragment of P14 cDNA which contains an IgE-binding epitope The 3'-region of P14 cDNA (bp 419-478) was cloned in the EcoRI site of lambda gtll and expressed as an IgE-binding polypeptide (21) as shown in FIG. 2. The β-galactosidase fusion protein (lane 4) bound strongly to IgE of the patient, while the control lanes 1 and 2 exhibited no IgE binding for the proteins of E. coli Y1089 and the proteins of E. coli Y1089 which were inoculated with lambda gtll phages without an insert. This example shows that a partial cDNA clone which codes for a protein having at least one epitope of the P14 molecule was obtained. It follows from this that partial cDNA clones which code for such incomplete P14 polypeptides may be useful for a therapy or diagnosis in a way similar to the complete P14 molecule or homologous proteins. 5.7. Demonstration of polynucleotides and polypeptides homologous to P14 within the order Fagales The Northern (RNA) blot (FIG. 3) shows that the P14 cDNA sequence (polynucleotide underlined in FIG. 4) is able to cross-hybridize with pollen mRNA from alder and hazel under stringent conditions (requirements of stringency are defined in 3. Summary of the Invention). Therefore, the sequence homology of the corresponding allergens of trees of the order Fagales can already be demonstrated at the nucleic acid level. FIG. 1A already showed a similar IgE-binding capacity of proteins of alder, hazel and hornbeam homologous to P14. It follows from this that P14 cDNA codes for polypeptides of similar IgE-binding capacity and antigenicity to closely related tree pollen allergens. 5.8. Seguence analysis FIG. 4 shows the sequence of the cDNA that codes for birch P14, and the deduced amino acid sequence of the coding region. It contains the complete protein coding region. The sequence of the peptide that, coupled to 6- galactosidase, represents an IgE-binding epitope is underlined in the figure (see Example 5.4). FIG. 5 illustrates the sequence homology between the P14 protein of birch and of human, mouse, calf, yeast and Acanthamoeba profilins (13, 12, 14, 11, 10). The cross-reactivity of patient IgE with birch P14 and human profilin is shown in FIG. 12. Similar chemical properties of these related proteins were likewise shown by their common affinity to poly(L-proline) (FIGS. 8 and 10) . These data indicate that the profilins of species which are as far apart in evolutionary terms as humans and birch are able to act as cross-reactive panallergens that may lead to an IgE autoimmune reactivity in patients. -19- 5.9. Expression of P14 coding cDNA in -i-- coli as fusion or nonfusion protein and detection of IgE-binding capacity of these polypeptides The polynucleotide given in FIG. 4 (nucleotides 1-710) that codes for birch P14 was inserted in the plasmid pKK223-3 so that a recombinant nonfusion protein (31) could be prepared, while a recombinant fusion protein wa- prod^-sed in the plasmid pEXB (32) . The reactivity of these pc peptides with patient IgE is shown in FIG. 6. Control protein extracts of E. coli in lanes 1, 2, 5 and 6 0 do not bind IgE, while recombinant birch P14 expressed as a nonfusion protein (lanes 3 and 4) and as a fusion prote..ι (lanes 7 and 8) does bind IgE. In FIG. 7, sera from persons allergic to birch pollen (A-K) , to grass pollen (L-N) and to mugwort (0-Q) 5 and of a pool of nonallergic individuals (R) , all of whom had been selected according to their case history, RAST and skin test, were tested for their IgE-binding capacity with recombinant birch P14. IgEs of Sera D, E, F, I, J and P bound to P14 expressed in pKK223-3. C It follows from this that this invention provides a polynucleotide that codes for polypeptides which have similar antigenicity and similar IgE-binding capacity to the P14 protein of birch when the polynucleotide is inser * d in the correct reading frame of 5 a variety of expression systems. The IgE-binding properties of these polypeptides were demonstrated for sera from patients who exhibit allergic reactions to various pollens and hence point to the great clinical 0 s nificance of these polypeptides (FIG. 7) . 5.10. Purification of P14 from pollen and of recombinant P14 from E. coli As described above, th-'s invention provides a 5 simple method for purifying natural as well as recombinant P14. The Coomassie-stained polyacrylamide gel in FIG. 8 shows that pure P14 (lanes 3, 4 and 5) can be separated from total pollen protein (lane 1) . The proteins which do not bind to poly(L-proline)-Sepharose are also shown (lane 2) . The effectiveness of this purification method was monitored by means of IgE im unoblotting (FIG. 9), and for this purpose serum from a patient who recognizes most -* birch pollen allergens with IgE antibodies (lane 1) was used. After application of the affinity method, almost no P14 can be found (lane 2) , while purif ed P14 was obtained in lanes 3, 4 and 5. FIG. 10 shows a polyacrylamide gel which 0 demonstrates the purification of recombinant P14 from E. coli JM105 that is transformed with the plasmid pKK223-3, which carries the P14 coding sequence. Recombinant P14 (lanes 3 and 4) was purified from the total proteins by affinity chromatography to poly(L-proline) sepharose (lane 5 1), the remaining proteins being shown by lane 2. FIG. 11 shows that no homologous protein from E. coli JM105 transformed with pKK223-3 without insert is obtained by means of the method used. As FIGS. 9, 6 and 7 show, the purified protein 0 (from birch and E. coli) retains its IgE-binding capacity. This example thus shows that the present invention likewise provides a simple and rapid purification method for P14 both as natural and recombinant polypeptide. Using poly(L-proline) to purify, both natural and 5 recombinant P14 retain their antigenicity and IgE binding capacity. In addition, the method offers the opportunity to immobilize (and separate by affinity means) the immunologically active polypeptide. 30 5.11. IgE reactivity of allergic and atopic patients with human profilin Various patient sera were selected as follows (FIG. 12) : Patient 1 shows IgE antibodies which are directed against most birch pollen allergens, including 35 Betvl and P14, patient 2 shows IgE binding only with P14 and patient 3 only with Betvl. Patient 4 is a person allergiσ to house dust mite and the serum pool 5 was made up of nonallergic individuals. Strip 6 is the buffer control. All these sera were tested for their IgE-binding capacity with nonrecombinant and recombinant P14 and human profilin. Those patients (FIG. 12), who recognized the 5 nonrecombinant P14 from birch as well as the recombinant P14 from J3. coli. also had IgE antibodies against human profilin. For this reason, this invention for the first time gives indications on the molecular level that autoimmune mechanisms might play a role in atopic and ° allergic diseases. Since patients with other autoimmune diseases form antibodies against P14, this invention should provide a diagnostic marker for these diseases. 5.12. Correlation of case histories of 5 atopic and allergic patients with the binding of IgE antibodies to P14 The case histories of patients who form IgE antibodies against P14 show that all of them suffer from severe allergic symptoms which are caused by a great 0 variety of allergens (tree and grass pollen, mite, cat and dog allergens) , that they have an elevated total IgE level and show an unsatisfactory course in hyposensitization therapy. It follows from this that a positive reaction of the serum IgE of patients with P14 is usable as a good 5 marker for the differentiation of certain groups of atopic and allergic patients. 5. 13. Demonstration of common IgE-epitopes between profilins in food (celery) and pollen P14 allergen (birch) The IgE-inhibition experiment shown in Figure .13 shows that there is common IgE-binding capacity of proteins homologous to the P14 allergen in pollens and food. Purified recombinant birch profilin, when added to the patients' serum in the fluid phase before the serum is incubated with the nitrocellulose bound celery profilin, is able to completely block the binding of patients' IgE to celery profilin. This indicates that the P14 allergen of birch (birch profilin) contains all IgE epitopes that can be found in celery profilin. Recombinant birch P14 allergen is therefore suitable not only for diagnosis and therapy of pollen allergies but also for food allergies. Common antigenicity of birch pollen P14 allergen and food profilins is also shown by crossreactivity of a rabbit anti celery profilin antibody with the pollen P14 allergen (Figs. 14 and 15). 5. 14. Sequence similarity and common IgE-binding capacity of pollen P14 allergen from white birch (Betula verrucosa) and the homologous P14(T) allergen from timothy grass (Phleum pratense). Amino acid sequence identity of birch P14 allergen and timothy grass P14(T) allergen is 77%. The cDNA encoding the P14(T) allergen from timothy grass was obtained by screening a cDNA library, which was constructed from pollen of timothy grass in the same way as described for the cDNA library from birch pollen, with patients' IgE as described for the P14 allergen of birch. The cDNA sequence of the clone encoding the P14(T) allergen of timothy grass is shown in Fig. 16. and as sequences 9-11 in the sequence listing. All patients' sera that bound with their IgE to birch profilin also bound with their IgE to sectors of nitrocellulose filters containing plaquelifts of immunopositive lambda gtl l phages into which the cDNA encoding timothy grass P14(T) allergen had been inserted (Fig. 17). "his shows that the proteins related to the P14 allergens by high homology also are immunologically cross reactive with patients' IgE antibodies. 6. METHODS OF ADMINISTRATION The present invention covers the use of P14 synthetic polypeptide allergens to hyposensitize or desensitize a mammal. Such polypeptides can be administered to a human subject either alone or in combination with pharmaceutically acceptable carriers or diluents, in accordance with standard pharmaceutical practice. The method of hyposensitization involves or could involve the successive parenteral, oral, nasal, inhalant or rectal administration of incremental doses of the P14 allergen. The term parenteral as used herein includes subcutaneous, intravenous or intramuscular injections. A range from 1 picogram to 10 milligrams per application can be used. The diluents and carriers can be chosen by those skilled in the art according to commonly accepted galenic procedures. 7. REFERENCES The references cited in the above specification are: 1. L. Yman, Botanical relations and immunological cross-reactions in pollen allergy, 2nd ed. Uppsala, Sweden: Pharmacia AB, 1982. 2. W. R. Thomas, K. Y. Chua, W. K. Greene and G. A. Stewart. Recombinant mite allergens. In: Epitopes of atopic allergens. A. H. Sehon, D. Kraft, and G. Kunkel (eds) . UCB Institute of Allergy, Brussels 1990. 3. E. Jarolim, M. Tejkl, M. Rohac, G. Schlerka, M. Breitenbach, O. Scheiner, D. Kraft, H. Rumpold. Monoclonal antibodies against birch pollen allergens; characterization by immunoblotting and use for single step affinity purification of the major allergen Betvl. Int. Arch. Allergy Appl. Immunol. 10., 54-60 (1989). 4. H. Ipsen, H. Bowadt, H. Janniche, B. Niichel Petersen, E. P. Munch, J. A. ihl and H. Lowenstein. Immunochemical characterization of reference alder (Alnus glutinosa) and hazel (Corylus avellana) pollen extracts and the partial immunochemical identity between the major allergens of alder, birch, and hazel pollen. Allergy 40., 510-518 (1985) . 5. H. Rumpold, M. Rohac, B. Bohle, M. Breitenbach, 0. Scheiner and D. Kraft. The relationship of Betvl epitopes recognized by patients* IgE and monoclonal anti-BetvI antibodies. In: Epitopes of atopic allergens. A. Sehon, D. Kraft and G. Kunkel (eds) . The UCB Institute of Allergy, Brussels 1990. 6. R. Valenta, H. Breiteneder, K. Pettenburger, M. Breitenbach, H. Rumpold, D. Kraft and 0. Scheiner. Homology of the major pollen allergens of alder, hazel, and hornbeam at the nucleic acid level as determined by cross-hybridization. J. Allergy Clin. Immunol., in press. 7. B. Nϋchel Petersen, H. Janniche, E.P. Munch, J. A. Wihl, H. Bδwadt, H. Ipsen and H. Lowenstein. Immunotherapy with partially purified and standardized tree pollen extracts. Allergy 4L, 353-362 (1988) . 8. J. A. Wihl, H. Ipsen, B. N chel Petersen, E. P. Munch, H. Janniche and H. Lowenstein. Immunotherapy with partially purified tree pollen extracts. Allergy 43., 363-369 (1988) . 9. H. Ipsen, B. Schwartz, J. A. Wihl, B. Nϋchel Petersen, E. P. Munch, H. Janniche and H. Lowenstein. Immunotherapy with partially purified and standardized tree pollen extracts. Allergy 43., 370-377 (1988) . 10. C. A pe, J. Vandekerckhove, S. L. Brenner, L. Tobacman and E. D. Korn. The amino acid sequence of Acanthamoeia profilin. J. Biol. Chem. 260. 834-840 (1985) . 11. V. Magdolen, U. Oechsner, G. Miiller and W. Bandlow. The intron-containing gene for yeast profilin (PFY) encodes a vital function. Mol. Cell. Biol. 8., 5108- 5115 (1988) . 12. J. S. Widada, C. Ferraz and J.-P. Liautard. Total coding sequence of profilin cDNA from us musculus macrophage. Nucl. Acids Res. 1 , 2855 (1989). 13. D. J. Kwiatkowski and G. A. P. Bruns. Human profilin. Molecular cloning, sequence comparison, and chromosomal analysis. J. Biol. Chem. 263. 5910-5915 (1988) . 14. C. A pe, F. Markey, U. Lindberg and J. Vandekerckhove. The primary structure of human platelet profilin: reinvestigation of the calf spleen profilin sequence. FEBS Lett. 228. 17-21 (1988) . 15. Lindberg, C. E. Schutt, E. Hellsten, A.-C. TjSder und T. Hult. The use of poly(L-proline)-Sepharose in the isolation of profilin and profilactin complexes. Biochim. Biophys. Acta 967. 391-400 (1988) . 16. M. Tanaka and H. Shibata. Poly(L-proline)- binding proteins from chick embryos are a profilin and a profilactin. Eur. J. Biochem. 151, 291-297 (1985) . 17. H. Breiteneder, W. Hassfeld, K. Pettenburger, E. Jarolim, M. Breitenbach, H. Rumpold, D. Kraft and O. Scheiner. Isolation and characterization of messenger RNA from male inflorescences and pollen of white birch (Betula verrucosa) . Int. Arch. Allergy Appl. Immunol. 87_, 19-24 (1988). 18. H. Aviv und P. Leder. Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose. Proc. Natl. Acad. Sci. USA 6£, 1408-1412 (1972) . . - -27- 19. T. V. Huynh, R. A. Young, R. W. Davis, In: DNA cloning - a practical approach, Band 1, D. M. Glover (ed) , ILL Press, Oxford 1985. 20. H. Hay erle. Nucl. Acids Res. l±, 8615 5 (1986) . 21. R. A. Young and R. W. Davis. Efficient isolation of genes by using antibody probes. Proc. Natl. Acad. Sci. USA BO, 1184-1198 (1983). 0 22. H. Breiteneder, K. Pettenburger, A. Bito, R. Valenta, D. Kraft, H. Rumpold, O. Scheiner and M. Breitenbach. The gene coding for the major birch pollen allergen Betvl is highly homologous to a pea disease 15 resistance response gene. EMBO J. 8., 1935-1938 (1989) . 23. F. M. Ausubel. Current protocols in molecular biology. Green Publishing Associates and Wiley- Interscience, New York, 1987. 0 24. C. Yanisch-Perron, J. Vieira and J. Messing. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mpl8 and pUC19 vectors. Gene 3_3, 103-119 (1985) . 5 25. F. Sanger, S. Nicklen and A. R. Coulson. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 7_i, 5463-54S7 (1977) . 0 26. R. B. Wallace, J. Shaffer, R. F. Murphy, J. Bonner, T. Hirose and K. Itakura. Hybridization of synthetic oligodeoxyribonucleotides to ΦX 174 DNA: the feet of a single base pair mismatch. Nucleic Acids Res. £, 3543-3557 (1979) . 5 27. P. S. Thomas. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc. Natl. Acad. Sci. USA 77., 5201-5205 (1980). 28. H. Lehrach. RNA molecular weight determinations by gel electrophoresis under denaturing conditions: a critical reexamination. Biochemistry 16, 4743-4751 (1977). 29. A. P. Feinberg and B. Vogelstein. A technique for radiolabeling DNA restriction fragments to high specific activity. Anal. Biochem. 132. 6-13 (1983) . 30. J. Shine and L. Dalgarno. The 3*-terminal sequence of Escherichia coli 16S ribosomal RNA: complementarity to nonsense triplets and ribosome binding sites. Proc. Natl. Acad. Sci. USA 71, 1342-1346 (1974). 31. E. Amann, J. Brosius and M. Ptashne. Vectors bearing a hybrid trp-lac promoter useful for regulated expression of cloned genes in Escherichia coli. Gene 2 , 167-178 (1983) . 32. N. Kiyoshi, H.C. Thøgersen. Generation of /3-globin by sequence-specific proteolysis of a hybrid protein produced in Escherichia coli. Nature 309. 810-812 (1984) . 33. D.M. Helfman, J.R. Feramisco, J.C. Fiddes, G.P. Thomas and S.H. Hughes. Identification of clones that encode chicken tropo yosin by direct immunological screening of a cDNA expression library. Proc. Natl. Acad. Sci. USA £0, 31-35 (1983). 8. SEQUENCE LISTING (1) GENERAL INFORMATION (i) APPLICANT: Dr. Rudolf Valenta Dr. Michael Duchene Mrs. Dr. Karin Pettenburger Dr. Michael Breitenbach Dr. Dietrich Kraft Dr. Helmut Rumpold Dr. Otto Scheiner (ii) TITLE OF INVENTION: Birch Pollen Allergen P14 or Diagnosis and Therapy of Allergic Diseases (iii) NUMBER OF SEQUENCES: 8 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Pennie & Edmonds (B) STREET: 1155 Avenue of the Americas (C) CITY: New York (D) STATE: New York (E) COUNTRY: USA (F) ZIP: 10036 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Diskette, 3.50 inch (B) COMPUTER: Hewlett Packard (IBM-PC Compatible) (C) OPERATING SYSTEM: MS-DOS (D) SOFTWARE: WordPerfect 5.1 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: 8 (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATE: (A) APPLICATION NUMBER: 07/353,844 (B) FILING DATE: May 18, 1989 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Harry C. Jones, III (B) REGISTRATION NUMBER: 20,280 (C) REFERENCE/DOCKET NUMBER: 6530-008 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (212) 790-9090 (B) TELEFAX: (212) 869-9741/8864 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 700 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA of mRNA (iϋ) HYPOTHETICAL: No (iv) ANTI-SENSE: No (v) FRAGMENT TYPE: Not Applicable (Vi) ORIGINAL SOURCE: (A) ORGANISM: Betula verrucosa (Vii) IMMEDIATE SOURCE: (A) POLLEN FROM ALLERGON AB, ENGELHOLM, SWEDEN (viii) POSITION IN GENOME: Not applicable (ix) FEATURE: Not Applicable (x) PUBLICATION INFORMATION: Not Applicable (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: CAGAGAAAGC GAAAGCTCTC CGCCACAACA AAACGAAGTA GAAGAAGAAG AGTGAGCAAG 60 AGACAGAGGG AAGAGGAAAA TGTCGTGGCA AACGTACGTG GATGAACATT TGATGTGCGA 120 TATCGACGGG CAAGCCAGCA ACTCGCTGGC ATCTGCGATC GTCGGTCACG ATGGCTCTGT 180 GTGGGCCCAG AGCTCTTCCT TCCCACAGTT TAAGCCTCAG- GAAATCACTG GTATCATGAA 240 GGACTTTGAG GAGCCGGGTC ATCTTGCTCC GACGGGCTTA CACCTTGGGG GCATAAAATA 300 CATGGTCATC CAGGGAGAGG CTGGTGCTGT CATCCGTGGA AAGAAGGGAT CTGGAGGTAT 360 TACTATAAAG AAGACTGGTG- AAGCTCTCGT TTTTGGCATC TATGAAGAGC CTGTGACACC 420 AGGACAGTGC AACATGGTTG TTGAGAGGTT GGGGGATTAC CTTATTGACC AGGGCCTGTA 480 GGCAAAGGTC TATCATCATT TGGGGCTTAA TTGTTTTTTT TTTTTTTTTG CTCTTATTCC 540 CTTTGATTTC GGTTCCAAGT GTGCATCGAT CTTCATTTGA AAGCCTTAAA TTGGCAGTGA 600 AGTTGTTGCA GACAATAACC ATGTGAGAAC TAAAACATTT GTCTTGTGTT TGGTTGTTTG 660 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 700 (3) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 399 nucleotides -31- (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: liner (ii) MOLECULE TYPE: cDNA of mRNA (iii) HYPOTHETICAL: No (iv) ANTI-SENSE: No (v) FRAGMENT TYPE: Not Applicable (vi) ORIGINAL SOURCE: (A) ORGANISM: Betula verrucosa (vii) IMMEDIATE SOURCE: (A) POLLEN FROM ALLERGON AB, ENGELHOLM, SWEDEN (viii) POSITION IN GENOME: Not Applicable (ix) FEATURE: Not Applicable (x) PUBLICATION INFORMATION: Not Applicable (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: ATGTCGTGGC AAACGTACGT GGATGAACAT TTGATGTGCG ATATCGACGG GCAAGCCAGC 60 AACTCGCTGG CATCTGCGAT CGTCGGTCAC GATGGCTCTG TGTGGGCCCA GAGCTCTTCC 120 TTCCCACACT TTAAGCCTCA GGAAATCACT GGTATCATGA AGGACTTTGA GGAGCCGGGT 180 CATCTTGCTC CGACGGGCTT ACACCTTGGG GGCATAAAAT ACATGGTCAT CCAGGGAGAG 240 GCTGGTGCTG TCATCCGTGG AAAGAAGGGA TCTGGAGGTA TTACTATAAA GAAGACTGGT 300 CAAGCTCTCG TTTTTGGCAT CTATGAAGAG CCTGTGACAC CAGGACAGTG CAACATGGTT 360 GTTGAGAGGT TGGGGGATTA CCTTATTGAC CAGGGCTG 399 (4) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 133 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: Not Applicable (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: No (iv) ANTI-SENSE: Not Applicable (v) FRAGMENT TYPE: Not Applicable (Vi) ORIGINAL SOURCE: (A) ORGANISM: Betula verrucosa (vii) IMMEDIATE SOURCE: Not applicable (viii) POSITION IN GENOME: Not applicable (ix) FEATURE: (D) OTHER INFORMATION : Amino acid sequence identity with profilin of other organisms is as follows : 30% with human profilin, 28% with calf and mouse , 26% with yeast and 25% with Acanthamoeba (x) PUBLICATION INFORMATION : Not Applicable (Xi) SEQUENCE DESCRIPTION : SEQ ID NO : 3 : Met Ser Trp Gin Thr Tyr Val Asp Glu His Leu Met Cys Asp He Asp 1 5 10 15 Gly Gin Ala Ser Asn Ser Leu Ala Ser Ala He Val Gly His Asp Gly 20 25 30 Ser Val Trp Ala Gin Ser Ser Ser Phe Pro Gin Phe Lys Pro Gin Glu 35 40 45 He Thr Gly He Met Lys Asp Phe Glu Glu Pro Gly His Leu Ala Pro 50 55 60 5 Thr Gly Leu His Leu Gly Gly He Lys Tyr Met Val He Gin Gly Glu 65 70 75 80 Ala Gly Ala Val He Arg Gly Lys Lys Gly Ser Gly Gly He Thr He 85 90 95 Lys Lys Thr Gly Gin Ala Leu Val Phe Gly He Tyr Glu Glu Pro Val 100 105 110 Q Thr Pro Gly Gin Cys Asn Met Val Val Glu Arg Leu Gly Asp Tyr Leu 115 120 125 He Asp Gin Gly Leu 130 5 (5) INFORMATION FOR SEQ ID NO: 4 : ( i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 140 amino acids (B) TYPE: amino acid (D) TOPOLOGY : linear Q ( ii) MOLECULE TYPE: peptide ( iii) HYPOTHETICAL: No (iv) ANTI-SENSE: Not applicable (v) FRAGMENT TYPE: Not Applicable (vi) ORIGINAL SOURCE: 5 (A) ORGANISM: MOUSE (Murine) (vii) IMMEDIATE SOURCE: Not applicable (viii) POSITION IN GENOME: Not applicable (ix) FEATURE: (D) OTHER INFORMATION : 28% identical with the P14 allergen of birch (Betula verrucosa) (X) PUBLICATION INFORMATION : ref . 12 (Xi) SEQUENCE DESCRIPTION : SEQ ID NO : 4 : Met Ala Gly Trp Asn Ala Tyr He Asp Ser Leu Met Ala Asp Gly Thr 1 5 10 15 Cys Gin Asp Ala Ala He Val Gly Tyr Lys Asp Ser Pro Ser Val Trp 20 25 30 Ala Ala Val Pro Gly Lys Thr Phe Val Ser He Thr Pro Ala Glu Val 35 40 45 Gly Val Leu Val Gly Lys Asp Arg Ser Ser Phe Phe Val Asn Gly Leu 50 55 60 Thr Leu Gly Gly Gin Lys Cys Ser Val He Arg Asp Ser Leu Leu Gin 65 70 75 80 Asp Gly Glu Phe Thr Met Asp Leu Arg Thr Lys Ser Thr Gly Gly Ala 85 90 95 Pro Thr Phe Asn Val Thr Val Thr Met Thr Ala Lys Thr Leu Val Leu 100 105 110 Leu Met Gly Lys Glu Gly Val His Gly Gly Leu He Asn Lys Lys Cys 115 120 125 Tyr Glu Met Ala Ser His Leu Arg Arg Ser Gin Tyr 130 135 140 (6) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 139 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Peptide (iii) HYPOTHETICAL: No (iv) ANTI-SENSE: Not applicable (v) FRAGMENT TYPE: Not Applicable (vi) ORIGINAL SOURCE: (A) ORGANISM: Calf (Bovine) (vii) IMMEDIATE SOURCE: Not applicable (viii) POSITION IN GENOME: Not applicable (ix) FEATURE: (D) OTHER INFORMATION: 28% identical with the P14 allergen of birch (Betula verrucosa) (X) PUBLICATION INFORMATION: ref.14 ( i) SEQUENCE DESCRIPTION: SEQ ID NO:5: Ala Gly Trp Asn Ala Tyr He Asp Asn Leu Met Ala Asp Gly Thr Cys 1 5 10 15 Gin Asp Ala Ala He Val Gly Tyr Lys Asp Ser Pro Ser Val Trp Ala 20 25 30 Ala Val Pro Gly Lys Thr Phe Val Asn He Thr Pro Ala Glu Val Gly 35 40 45 He Leu Val Gly Lys Asp Arg Ser Ser Phe Phe Val Asn Gly Leu Thr 50 55 60 Leu Gly Gly Gin Lys Cys Ser Val He Arg Asp Ser Leu Leu Gin Asp 65 70 75 80 Gly Glu Phe Thr Met Asp Leu Arg Thr Lys Ser Thr Gly Gly Ala Pro 85 90 95 Thr Phe Asn He Thr Val Thr Met Thr Ala Lys Thr Leu Vai Leu Leu 100 105 110 Met Gly Lys Gin Gly Val His Gly Gly Met He Asn Lys Lys Cys Tyr 115 120 125 Glu Met Ala Ser His Leu Arg Arg Ser Gin Tyr 130 135 (7) INFORMATION FOR SEQ ID NO:6 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 140 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Peptide (iii) HYPOTHETICAL: No (iv) ANTI-SENSE: Not applicable (v) FRAGMENT TYPE: Not Applicable (vi) ORIGINAL SOURCE: (A) ORGANISM: Human (Homo sapiens) (vii) IMMEDIATE SOURCE: Not applicable (viii) POSITION IN GENOME: Not applicable (ix) FEATURE: (D) OTHER INFORMATION: 30% identical with the P14 allergen of birch (Betula verrucosa) (x) PUBLICATION INFORMATION: ref. 13 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Met Ala Gly Trp Asn Ala Tyr He Asp Asn Leu Met Ala Asp Gly Thr 1 5 10 15 Cys Gin Asp Ala Ala He Val Gly Tyr Lys Asp Ser Pro Ser Val Trp 20 25 30 Ala Ala Val Pro Gly Lys Thr Phe Val Asn He Thr Pro Ala Glu Val 35 40 45 Gly Val Leu Val Gly Lys Asp Arg Ser Ser Phe Tyr Val Asn Gly Leu 50 55 60 Thr Leu Gly Gly Gin Lys Cys Ser Val He Arg Asp Ser Leu Leu Gin 65 70 75 80 Asp Gly Glu Phe Ser Met Asp Leu Arg Thr Lys Ser Thr Gly Gly Ala 85 90 95 Pro Thr Phe Asn Val Thr Val Thr Lys Thr Asp Lys Thr Leu Val Leu 100 105 110 Leu Met Gly Lys Glu Gly Val His Gly Gly Leu He Asn Lys Lys Cys 115 120 125 Tyr Glu Met Ala Ser His Leu Arg Arg Ser Gin Tyr 130 135 140 (8) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 126 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Peptide (iii) HYPOTHETICAL: No (iv) ANTI-SENSE: Not applicable (v) FRAGMENT TYPE: Not applicable (Vi) ORIGINAL SOURCE: (A) ORGANISM: Yeast (vii) IMMEDIATE SOURCE: Not applicable (viii) POSITION IN GENOME: Not applicable (ix) FEATURE: (D) OTHER INFORMATION: 26% identical with the P14 allergen of birch (Betula verrucosa ) (X) PUBLICATION INFORMATION: ref. 11 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Met Ser Trp Gin Ala Tyr Thr Asp Asn Leu He Gly Thr Gly Lys Val 1 5 10 15 Asp Lys Ala Val He Tyr Ser Arg Ala Gly Asp Ala Val Trp Ala Thr 20 25 30 Ser Gly Gly Leu Ser Leu Gin Pro Asn Glu He Gly Glu He Val Gin 35 40 45 Gly Phe Asp Asn Pro Ala Gly Leu Gin Ser Asn Gly Leu His He Gin 50 55 60 Gly Gin Lys Phe Met Leu Leu Arg Ala Asp Asp Arg Ser He Tyr Gly 65 70 75 80 Arg His Asp Ala Glu Gly Val Val Cys Val Arg Thr Lys Gin Thr Val 85 90 95 He He Ala His Tyr Pro Pro Thr Val Gin Ala Gly Glu Ala Thr Lys 100 105 110 He Val Glu Gin Leu Ala Asp Tyr Leu He Gly Val Gin Tyr 115 120 125 5 ( 9 ) INFORMATION FOR SEQ ID NO: 8 : ( i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 125 amino acids (B) TYPE: amino acid (D) TOPOLOGY : linear 0 ( ϋ) MOLECULE TYPE : Peptide ( iii) HYPOTHETICAL : No ( iv) ANTI-SENSE : Not applicable (v) FRAGMENT TYPE : Not Applicable (Vi) ORIGINAL SOURCE : 5 (A) ORGANISM: Acanthamoeba (vii) IMMEDIATE SOURCE: Not applicable (viii) POSITION IN GENOME : Not applicable ( ix) FEATURE: (D) OTHER INFORMATION : 25% identical with 0 the P14 allergen of birch ( Betula verrucosa) (x) PUBLICATION INFORMATION : ref . 10 (Xi) SEQUENCE DESCRIPTION : SEQ ID NO : 8 : Thr Trp Gin Ser Tyr Val Asp Thr Asn Leu Val Gly Thr Gly Ala Val 1 5 10 15 „_ Thr Gin Ala Ala He Leu Gly Leu Asp Gly Asn Thr Trp Ala Ser Phe JD 20 25 30 Ala Gly Phe Ala Val Thr Pro Ala Gin Gly Thr Thr Leu Ala Gly Ala 35 40 45 Phe Asn Asn Ala Asp Ala He Arg Ala Gly Gly Phe Asp Leu Ala Gly 50 55 60 Val His Tyr Val Thr Leu Arg Ala Asp Asp Arg Ser He Tyr Gly Lys 65 70 75 80 Lys Gly Ala Ser Gly Val He Thr Val Lys Thr Ser Lys Ser He Leu 85 90 95 Val Gly Val Tyr Asn Glu Lys He Gin Pro Gly Thr Ala Ala Asn Val 100 105 110 Val Glu Lys Leu Ala Asp Tyr Leu He Gly Gin Gly Phe 115 120 125 (10) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 641 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA of mRNA (iii) HYPOTHETICAL: No (iv) ANTI-SENSE: No (v) FRAGMENT TYPE: Not applicable (vi) ORIGINAL SOURCE: (A) ORGANISM: Phleum pratense (vii) IMMEDIATE SOURCE: (A) Pollen from Allergon AB, Engelholm, Sweden (viii) POSITION IN GENOME: Not applicable (ix) FEATURE: Not applicable (x) PUBLICATION INFORMATION: Not applicable (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: GAAAGCAAACTTGCAGGACCGAAGATGTCGTGGCAGACGTACGTGGACGAGCACCTGATG 60 TGCGAGATCGAGGGCCACCACCTCGCCTCGGCGGCCATCCTCGGCCACGACGGCACCGTC 120 TGGGCCCAGAGCGCCGACTTCCCCCAGTTCAAGCCTGAGGAGATCACCGGCATCATGAAG 180 GATTTCGACGAGCCGGGGCACCTCGCCCCCACCGGCATGTTCGTCGCAGGTGCCAAGTAC 240 ATGGTCATCCAGGGTGAACGGGGTCGCGTCATCCGTGGCAAGAAGGGAGCAGGAGGCATC 300 ACCATAAAGAAGACCGGGCAGGCGCTGGTCGTCGGCATCTATGACGAGCCCATGACCCCT 360 GGGCAGTGCAACATGGTGGTGGAGAGGCTTGGCGACTACCTCGTTGAACAAGGCATGTAG 420 ACTGGCTGATCCATGGCTTCCACGTCTCCACGATCGATGATGATCATACAGTTTTTCACG 80 TTCTTTTAAACATCTATTGGAATATATATGGGGCTTCTCCTCTTTTACCGGCTCTGGTCA 540 TGGATCACTGATGACCAGTTGCTCTGGAAGTTTCATTTGTAATGCCATCTTGGCTTTCTA 600 TCTTCTTCAATGTTTTTTTTTTCTTTTCGGTTAAAAAAAAA 64 (11) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 393 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA of mRNA, coding region (iii) HYPOTHETICAL: No (iv) ANTI-SENSE: No (v) FRAGMENT TYPE: Not applicable (vi) ORIGINAL SOURCE: (A) ORGANISM: Phleu pratense (vii) IMMEDIATE SOURCE: (A) Pollen from Allergon AB, Engelholm, Sweden (viii) POSITION IN GENOME: Not applicable (ix) FEATURE: Not applicable (x) PUBLICATION INFORMATION: Not applicable (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: ATGTCGTGGCAGACGTACGTGGACGAGCACCTGATGTGCGAGATCGAGGGCCACCACCTC 60 GCCTCGGCGGCCATCCTCGGCCACGACGGCACCGTCTGGGCCCAGAGCGCCGACTTCCCC 120 CAGTTCAAGCCTGAGGAGATCACCGGCATCATGAAGGATTTCGACGAGCCGGGGCACCTC 180 GCCCCCACCGGCATGTTCGTCGCAGGTGCCAAGTACATGGTCATCCAGGGTGAACCCGGT 240 C .GTC-ATCCGTGGCAAGAAGGGAGCAGGAGGCATCACCATAAΑGAAGACCGGGCAGGCG 300 C GGTCGTCGGCATCTATGACGAGCCCATGACCCCTGGGCAGTGCAACATGGTGGTGGAG 360 AGGCTTGGCGACTACCTCGTTGAACAAGGCATG 393 (12) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 amino acid residues (B) TYPE: amino acid (C) STRANDEDNESS: Not applicable (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide, P14(T) allergen (iii) HYPOTHETICAL: No (iv) ANTI-SENSE: Not applicable (v) FRAGMENT TYPE: Not applicable (vi) ORIGINAL SOURCE: (A) ORGANISM: Phleum pratense (vii) IMMEDIATE SOURCE: Not applicable (viii) POSITION IN GENOME: Not applicable (ix) FEATURE: Amino acid identity with P14 allergen from Betul verrucosa is 77% (x) PUBLICATION INFORMATION: Not applicable (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: 1 5 10 15 Met Ser Trp Gin Thr Tyr Val Asp Glu His Leu Met Cys Glu He 20 25 30 Glu Gly His His Leu Ala Ser Ala Ala He Leu Gly His Asp Gly 35 40 45 Thr Val Trp Ala Gin Ser Ala Asp Phe Pro Gin Phe Lys Pro Glu 50 55 60 Glu He Thr Gly He Met Lys Asp Phe Asp Glu Pro Gly His Leu 65 70 75 Ala Pro Thr Gly Met Phe Val Ala Gly Ala Lys Tyr Met Val He 80 85 90 Gin Gly Glu Pro Gly Arg Val He Arg Gly Lys Lys Gly Ala Gly 95 100 105 Gly He Thr He Lys Lys Thr Gly Gin Ala Leu Val Val Gly He 110 115 120 Tyr Asp Glu Pro Met Thr Pro Gly Gin Cys Asn Met Val Val Glu 125 130 Arg Leu Gly Asp Tyr Leu Val Glu Gin Gly Met

Claims: hat is claimed is: 1. A recombinant DNA molecule, comprising DNA coding for a polypeptide having at least one epitope of a P14 allergen of grass, weeds and trees of the order Fagales. 2. A recombinant DNA molecule according to claim 1, wherein the allergen is selected from P14 allergens of the group consisting of birch, alder, hazel, hornbeam and oak. 3. A recombinant DNA molecule according to claim 1, wherein the allergen is a P14 allergen of birch. 4. A recombinant DNA molecule according to claim 1, 2 or 3, which codes for a polypeptide having the entire amino acid sequence of the P14 allergen. 5. A recombinant DNA molecule according to claim 3, which codes for a polypeptide having all or part of the amino acid sequence as defined in the Sequence Listing by SEQ ID Nϋ:3. 6. A replicable microbial expression vehicle capable, in a transformant host organism, of being replicated and of directing expression of a DNA of claims 1, 2, 3 or 5 to produce said polypeptide. 7. A replicable microbial expression vehicle capable, in a transformant host organism, of being replicated and of directing expression of a DNA of claim 4 to produce said polypeptide. 8. A prokaryotic or eukaryotic host organism transformed with a microbial expression vehicle capable, in said organism, of being replicated and of directing expression of a DNA of claim 1, 2, 3 or 5 to produce said polypeptide. 9. A prokaryotic or eukaryotic host organism transformed with a microbial expression vehicle capable, ° in said organism, of being replicated and of directing expression of a DNA of claim 4 to produce said polypeptide. 10. A host organism according to claim 8, 0 wherein the host organism is Escherichia coli. " 11. A host organism according to claim 9, wherein the host organism is Escherichia coli. 5 12. A method for producing a polypeptide having at least one epitope of a P14 allergen, comprising culturing a host organism containing a microbial expression vehicle capable, in said host organism, of being replicated and of directing expression of a DNA of 0 claim 1, 2, 3 or 5 to produce said polypeptide. 13. A method for producing a polypeptide having at least one epitope of a P14 allergen, comprising culturing a host organism containing a microbial 5 expression vehicle capable, in said host organism, of being replicated and of directing expression of a DNA of claim 4 to produce'said polypeptide. 14. A composition comprising a polypeptide 0 having at least one epitope of a P14 allergen and produced by a method according to claim 12. 15. A composition comprising a polypeptide having at least one epitope of a P14 allergen and produced 35 by a method according to claim 13. 16. A composition comprising a polypeptide having at least one epitope of a P14 allergen and produced by chemical synthesis according to the whole or a part of SEQ ID NO:3. 17. A method for detecting antibodies, comprising contacting serum of a mammal with a composition according to claim 14, and detecting any immunological reaction between antibodies in the serum and said polypeptide having at least one epitope of a P14 allergen. 18. A method according to claim 17, wherein the detected antibody is an IgE antibody. 19. A method for detecting antibodies, comprising contacting serum of a mammal with a composition according to claim 15, and detecting any immunological reaction between antibodies in the serum and said polypeptide having at least one epitope of a P14 allergen. 20. A method according to claim 19, wherein the detected antibody is an IgE antibody. 21. A method for detecting antibodies, comprising contacting serum of a mammal with a composition according to claim 16, and detecting any immunological reaction between antibodies in the serum and said polypeptide having at least one epitope of a P14,-allergen. 22. A method according to claim 21, wherein the detected antibody is an IgE antibody. 23. A method for detecting in vitro the cellular reaction to P14 allergen, comprising contacting mammalian cells with a composition according to claim 14, and detecting the reaction of said cells. 24. A method for detecting in vitro the cellular reaction to P14 allergen, comprising contacting mammalian cells with a composition according to claim 15, and detecting the reaction of said cells. 25. A method for detecting in vitro the cellular reaction to P14 allergen, comprising contacting mammalian cells with a composition according to claim 16, and detecting the reaction of said cells. 26. A method for treating a mammai afflicted with a pollen allergy, comprising administering an effective amount of a composition according to claim 14 to hyposensitize said mammal. 27. A method for treating a mammal afflicted with a pollen allergy, comprising administering an effective amount of a composition according to claim 15 to hyposensitize said mammal. 28. A method for treating a mammal afflicted with a pollen allergy, comprising administering an effective amount of a composition according to claim 16 to hyposensitize said mammal. 29. A method for detecting allergic reactions to a P14 allergen, comprising administering a composition according to claim 14, so as to elicit bronchial, conjunctival, dermal, nasal or oral provocation of a mammal, and detecting any immunological reaction between said organs and said polypeptide. 30. A method for detecting allergic reactions to a P14 allergen, comprising administering a composition according to claim 15, so as to elicit bronchial, conjunctival, dermal, nasal or oral provocation of a mammal, and detecting any immunological reaction between said organs and said polypeptide. 31. A method for detecting allergic reactions to a P14 allergen, comprising administering a composition according to claim 16, so as to elicit bronchial, conjunctival, dermal, nasal or oral provocation of a mammal, and detecting any immunological reaction between said organs and said polypeptide. 32. A method for detecting the presence of a P14 allergen, comprising, contacting a sample suspected of containing a P14 allergen with poly(L-proline) , and detecting any reaction between any P14 allergen and the poly(L-proline) . 33. A method for purifying a P14 allergen or a polypeptide having the antigenicity of a P14 allergen, comprising binding any P14 allergen in a sample to poly(L- proline) , and collecting the bound P14 allergen.

Inventors: BREITENBACH MICHAEL, DUCHENE MICHAEL, KRAFT DIETRICH, PETTENBURGER KARIN, RUMPOLD HELMUT, SCHEINER OTTO, VALENTA RUDOLF, BREITENBACH, MICHAEL, DUCHENE, MICHAEL, KRAFT, DIETRICH, PETTENBURGER, KARIN, RUMPOLD, HELMUT, SCHEINER, OTTO, VALENTA, RUDOLF
Applicants: BIOMAY BIOTECH PROD, BIOMAY BIOTECHNIK PRODUKTIONS- UND HANDELSGESELLSC
Application year: 1991
Main classification: A61K37
IPC codes: A61K38, C07K1, C07K14, C12N1, C12N15, C12P21, C12Q1, C12R1